Influence of obesity on breast cancer receptor status and prognosis

References

• Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol.3(9), 565–574 (2002).
   PubMed Web of Science ®Google Scholar
• Vona-Davis L, Howard-McNutt M, Rose DP. Adiposity, Type 2 diabetes and the metabolic syndrome in breast cancer. Obes. Rev.8(5), 395–408 (2007).
   PubMed Web of Science ®Google Scholar
• Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr. Cancer45(1), 1–16 (2003).
   PubMed Web of Science ®Google Scholar
• Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int. J. Cancer122(5), 1089–1094 (2008).
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res.13(15 Pt 1), 4429–4434 (2007).
   PubMed Web of Science ®Google Scholar
• Vona-Davis L, Rose DP, Hazard H et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol. Biomarkers Prev.17(12), 3319–3324 (2008).
   PubMed Web of Science ®Google Scholar
• Chang S, Masse LC, Moser RP et al. State ranks of incident cancer burden due to overweight and obesity in the USA, 2003. Obesity (Silver Spring)16(7), 1636–1650 (2008).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J. Clin. Oncol.20(4), 1128–1143 (2002).
   PubMed Web of Science ®Google Scholar
• Berclaz G, Li S, Price KN et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann. Oncol.15(6), 875–884 (2004).
   PubMed Web of Science ®Google Scholar
• Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol. Biomarkers Prev.14(8), 2009–2014 (2005).
   PubMed Web of Science ®Google Scholar
• Cleveland RJ, Eng SM, Abrahamson PE et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol. Biomarkers Prev.16(9), 1803–1811 (2005).
   Web of Science ®Google Scholar
• Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J. Clin. Oncol.6(12), 3731–3735 (1998).
   Google Scholar
• Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res. Treat.64(2), 157–163 (2000).
   PubMed Web of Science ®Google Scholar
• Enger SM, Greif JM, Polikoff J, Press M. Bodyweight correlates with mortality in early-stage breast cancer. Arch. Surg.139(9), 954–958 (2007).
   Google Scholar
• Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr. Cancer44(2), 127–138 (2002).
   PubMed Web of Science ®Google Scholar
• Huang Z, Willett WC, Colditz GA et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am. J. Epidemiol.150(12), 1316–1324 (1999).
   PubMed Web of Science ®Google Scholar
• Olson MB, Shaw LJ, Kaizar EE et al. Obesity distribution and reproductive hormone levels in women: a report from the NHLBI-sponsored WISE study. J. Womens Health (Larchmt)15(7), 836–842 (2006).
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Bahl M et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res. Treat.114(3), 517–525 (2009).
   PubMed Web of Science ®Google Scholar
• Borugian MJ, Sheps SB, Kim-Sing C et al. Waist-to-hip ratio and breast cancer mortality. Am. J. Epidemiol.158(10), 963–968 (2003).
   PubMed Web of Science ®Google Scholar
• Maehle BO, Tretli S, Thorsen T. The associations of obesity, lymph node status and prognosis in breast cancer patients: dependence on estrogen and progesterone receptor status. APMIS112(6), 349–357 (2004).
   PubMed Web of Science ®Google Scholar
• Porter GA, Inglis KM, Wood LA, Veugelers PJ. Effect of obesity on presentation of breast cancer. Ann. Surg. Oncol.13(3), 327–332 (2006).
   PubMed Web of Science ®Google Scholar
• Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer92(4), 720–729 (2001).
   PubMed Web of Science ®Google Scholar
• Hunt KA, Sickles EA. Effect of obesity on screening mammography: outcomes analysis of 88,346 consecutive examinations. AJR Am. J. Roentgenol.174(5), 1251–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect. Prev.25(1), 16–31 (2001).
   PubMedGoogle Scholar
• Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African–American and white American women. Endocr. Rev.28(7), 763–777 (2007).
   PubMed Web of Science ®Google Scholar
• Cui Y, Whiteman MK, Langenberg P et al. Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women? J. Womens Health Gend. Based Med.11(6), 527–536 (2002).
   PubMedGoogle Scholar
• Porter PL, Lund MJ, Lin MG et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer100(12), 2533–2542 (2004).
   PubMed Web of Science ®Google Scholar
• Borgquist S, Jirstrom K, Anagnostaki L, Manjer J, Landberg G. Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer. Int. J. Cancer124(2), 402–411 (2009).
   PubMed Web of Science ®Google Scholar
• Oestreicher N, White E, Malone KE, Porter PL. Hormonal factors and breast tumor proliferation: do factors that affect cancer risk also affect tumor growth? Breast Cancer Res. Treat.85(2), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer48(4), 974–979 (1981).
   PubMed Web of Science ®Google Scholar
• McGurrin JF, Doria MI Jr, Dawson PJ, Karrison T, Stein HO, Franklin WA. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer59(10), 1744–1750 (1987).
   PubMed Web of Science ®Google Scholar
• Demirkan B, Alacacioglu A, Yilmaz U. Relation of body mass index (BMI) to disease free (DFS) and distant disease free survivals (DDFS) among Turkish women with operable breast carcinoma. Jpn. J. Clin. Oncol.37(4), 256–265 (2007).
   PubMed Web of Science ®Google Scholar
• Loi S, Milne RL, Friedlander ML et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev.14(7), 1686–1691 (2005).
   PubMed Web of Science ®Google Scholar
• Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev.5(3), 153–165 (2004).
   PubMedGoogle Scholar
• Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obes. (Lond.)29(11), 1308–1314 (2005).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Gonzalez-Angulo AM et al. Prognostic value of body mass index in locally advanced breast cancer. Clin. Cancer Res.14(6), 1718–1725 (2008).
   PubMed Web of Science ®Google Scholar
• Amend K, Hicks D, Ambrosone CB. Breast cancer in African–American women: differences in tumor biology from European–American women. Cancer Res.66(17), 8327–8330 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg LU, Einarsdottir K, Friman EI et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev.15(12), 2482–2488 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Bodyweight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int. J. Cancer119(7), 1683–1689 (2006).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J. Natl Cancer Inst.96(3), 218–228 (2004).
   PubMed Web of Science ®Google Scholar
• Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG, Hormone-related factors and risk of breast cancer in relation to estrogen and progesterone receptor status. Am. J. Epidemiol.151(7), 703–714 (2000).
   PubMed Web of Science ®Google Scholar
• Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L. Body size, physical activity, and breast cancer hormone receptor status: results from two case–control studies. Cancer Epidemiol. Biomarkers Prev.9(7), 681–687 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Bodyweight and incidence of breast cancer defined by estrogen and progesterone receptor status – a meta-analysis. Int. J. Cancer124(3), 698–712 (2009).
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J. Clin. Oncol.26(9), 1419–1426 (2008).
   PubMed Web of Science ®Google Scholar
• Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to III breast cancer in young women. J. Am. Coll. Surg.190(5), 523–529 (2000).
   PubMed Web of Science ®Google Scholar
• Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res. Treat.78(1), 105–118 (2003).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple-negative tumors: a critical review. Histopathology52(1), 108–118 (2008).
   PubMed Web of Science ®Google Scholar
• Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol.24(36), 5652–5657 (2006).
   PubMed Web of Science ®Google Scholar
• Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat.115(2), 423–428 (2008).
   PubMed Web of Science ®Google Scholar
• Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat.109(1), 123–139 (2008).
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Endogenous Hormones and Breast Cancer Collaborative Group. J. Natl Cancer Inst.94(8), 606–616 (2002).
   PubMed Web of Science ®Google Scholar
• Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol. Biomarkers Prev.13(2), 220–224 (2004).
   PubMed Web of Science ®Google Scholar
• De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R. Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity (Silver Spring)14(11), 1954–1960 (2006).
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol.20(1), 42–51 (2002).
   PubMed Web of Science ®Google Scholar
• Borugian MJ, Sheps SB, Kim-Sing C et al. Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol. Biomarkers Prev.13(7), 1163–1172 (2004).
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med.358(19), 2039–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor1 but not interleukin-6 release by human adipocytes. Metabolism54(2), 220–226 (2005).
   PubMed Web of Science ®Google Scholar
• Bermont L, Lamielle F, Lorchel F et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J. Clin. Endocrinol. Metab.86(1), 363–368 (2001).
   PubMed Web of Science ®Google Scholar
• Shrader CD, Bailey KM, Konat GW, Cilento EV, Reilly FD. Insulin enhances proliferation and viability of human umbilical vein endothelial cells. Arch. Dermatol. Res.301(2), 159–166 (2009).
   PubMed Web of Science ®Google Scholar
• Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr. Relat. Cancer14(2), 189–206 (2007).
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin. Cancer Res.10(13), 4325–4331 (2004).
   PubMed Web of Science ®Google Scholar
• Liu CL, Chang YC, Cheng SP et al. The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology72(1–2), 75–81 (2007).
   PubMed Web of Science ®Google Scholar
• Ligibel JA, Campbell N, Partridge A et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J. Clin. Oncol.26(6), 907–912 (2008).
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J. Clin. Oncol.23(7), 1370–1378 (2005).
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch. Intern. Med.165(11), 1267–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J. Natl Cancer Inst.95(19), 1467–1476 (2003).
   PubMedGoogle Scholar
• Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer8(6), 501–505 (2008).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Blackburn GL, Thomson CA et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J. Natl Cancer Inst.98(24), 1767–1776 (2006).
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Wieand K, Johnson KA et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res. Treat.97(3), 245–254 (2006).
   PubMed Web of Science ®Google Scholar
• Braithwaite D, Tammemagi CM, Moore DH et al. Hypertension is an independent predictor of survival disparity between African–American and white breast cancer patients. Int. J. Cancer124(5), 1213–1219 (2009).
   PubMed Web of Science ®Google Scholar